EGFR and central nervous system cancer: Alternatively, downregulation of EGFRvIII activation at both tyrosine phosphorylation and expression levels by the combination treatment may be important to suppress the signaling from EGFR that contributes to growth and survival benefits for glioma cells in vivo.